POM WONDERFUL LLC, Plaintiff, v. The FEDERAL TRADE COMMISSION, Defendant.
Civil Action No. 10-1539 (RWR).
United States District Court, District of Columbia.
Sept. 30, 2012.
III. CONCLUSION
For the foregoing reasons, the Court concludes that under the Rooker-Feldman doctrine, Steven Alan Magritz, who lost a foreclosure action in Wisconsin, cannot seek review of that Wisconsin judgment in federal court. Accordingly, defendants’ June 27 Motion to Dismiss is hereby GRANTED. Although not specifically raised by defendants Gerol, Williams and Gonring in the July 6 Motion to Dismiss, the Court finds that it lacks subject matter jurisdiction over the claims asserted against those defendants for the same reasons explained above. See Evans v. Suter, No. 09-5242, 2010 WL 1632902, at *1 (D.C.Cir. Apr. 2, 2010); Hurt v. U.S. Court of Appeals for the D.C.Cir., 264 Fed.Appx. 1, 1 (D.C.Cir.2008) (affirming district court‘s dismissal of pro se complaint because “[i]t was proper for the district court to analyze its own jurisdiction sua sponte and dismiss the case for lack of jurisdiction“); see
SO ORDERED.
Drake S. Cutini, Department of Justice, Washington, DC, for Defendant.
MEMORANDUM OPINION
RICHARD W. ROBERTS, District Judge.
Plaintiff POM Wonderful LLC (“POM“), the largest processor and distributor of pomegranate products in the United States, brings an action against the Federal Trade Commission (“FTC“) under the
BACKGROUND
In July 2010, the FTC entered written agreements with two companies whose advertisements overstated their products’ effect on disease prevention, mitigation, and treatment. See Stipulated Final J. and Order for Permanent Inj. and Other Equitable Relief, FTC v. Iovate Health Scis. USA, Inc., et al. (“Iovate“), No. 10-cv-587 (W.D.N.Y. July 29, 2010); Agreement Containing Consent Order, In the Matter of Nestlé HealthCare Nutrition, Inc. (“Nestlé“), No. 092-3087, 2010 WL 2811203 (F.T.C. July 14, 2010). Both agreements required the companies to root their future health claims in “competent and reliable scientific evidence ... consist[ing] of at least two adequate and well-controlled human clinical studies of the [product.]” See Iovate at 7; Nestlé at 4. (See also Compl. ¶¶ 6, 28.) The Nestlé agreement also provided that all disease-based representations be pre-approved by the Food and Drug Administration (“FDA“). Nestlé at 3. (See also Compl. ¶ 27.)
According to POM, these new standards departed from “over twenty years of FTC food advertising rules and regulations[.]” (Compl. ¶¶ 5, 25; see also id. ¶ 28.) POM alleged that the FTC had never before “requir[ed] prior FDA approval” irrespective of whether the claims “are true or supported by competent, reliable scientific evidence[.]” (Id. ¶ 25(2).) Neither had the FTC earlier implemented a heightened standard for scientific studies. (Id. ¶ 25(1).) Rather than codifying the new requirements in formal regulations, the FTC allegedly expressed its intention to “universally apply[]” them against the food and dietary supplement industry as an enforcement mechanism for deceptive advertising. (Compl. ¶¶ 5, 23-24.) POM alleges that the requirements do not merely “interpret[ ] present standards or rules.” (Id. ¶ 25(1).) Instead, they “constitute a final agency action within the meaning of” the APA. (Id. ¶¶ 35, 42, 48, 54.)
POM alleges that by adopting these new rules, the FTC violated statutory and constitutional law. Thus, POM seeks declaratory judgment that the FTC exceeded its statutory authority under Sections 51 and 122 of the FTC Act by encroaching upon the FDA‘s authority, see
On September 27, 2010, approximately two weeks after POM filed the instant case, the FTC filed against POM an administrative complaint alleging that “POM‘s practices in promoting pomegranate juice and pills constitute unfair or deceptive acts or practices and false advertising in violation of sections 5(a) and 12 of the FTC Act[.]” (Def.‘s Mem. in Supp. of Mot. to Dismiss by FTC (“Def.‘s Mem.“) to Dismiss at 5.)5 In the enforcement action, the FTC is seeking an order that would forbid POM from making certain claims about the health benefits of its products unless “the representation is non-misleading” and the FDA has approved the claims. (Compl. at 21–22, In the Matter of POM Wonderful, et al., No. 9344 (F.T.C. Sept. 27, 2010).) The proposed order would also limit the representations that POM can make about its products and establish substantial future oversight by the FTC. (Id. at 22-25.)
In POM‘s answer to the FTC‘s complaint, it asserted a number of affirmative defenses. POM argued that “[t]he FTC lacks authority to impose all or part of the relief sought under the FTC Act, the Administrative Procedure Act, and the First and Fifth Amendments of the U.S. Constitution.” (Answer at 7, In the Matter of POM Wonderful, et al., No. 9344 (F.T.C. Oct. 18, 2010).) It also alleged that the FTC has taken a new position in the enforcement action against it “without adequate notice to the public.” (Id.)
The FTC moves to dismiss this action, in part, because this court should exercise its discretion to decline to entertain POM‘s declaratory judgment action. (Def.‘s Mem. at 10.) Relying on Swish Marketing, Inc. v. FTC, 669 F.Supp.2d 72 (D.D.C. 2009), the FTC argues that declaratory relief is not proper because a declaratory judgment would not fully resolve the controversy between the parties, POM‘s claims raised in this complaint can be raised in the pending administrative action, and POM‘s complaint anticipates defenses. (Id.) POM counters that Swish should be distinguished because the plaintiff in Swish was atypical in that it had “already agreed to stop its allegedly unlawful conduct. Thus, the plaintiff‘s liability to the defendant as to future damages if any ... [had] now been frozen, so a prompt and speedy adjudication of [the plaintiff‘s] rights in order to protect it from acting at its peril or avoiding damages in the future [was] unnecessary,” Swish Mktg., 669 F.Supp.2d at 77 (internal citations and quotation marks omitted). (Pl.‘s Mem. of P. & A. in Opp‘n to Def. FTC‘s Mot. to Dismiss at *9.) POM also asserts that its complaint does not attempt
DISCUSSION
The Declaratory Judgment Act allows district courts to “declare the rights and other legal relations of any interested party seeking such declaration.”
“There are no dispositive factors” a district court should consider in determining whether it should entertain an action brought under the Declaratory Judgment Act. See Comm. on Judiciary v. Miers, 558 F.Supp.2d 53, 95 (D.D.C.2008). However, the D.C. Circuit has found to be useful considerations:
Hanes, 531 F.2d at 592 n. 4; see also Swish Mktg., 669 F.Supp.2d at 76-77 (D.D.C.2009).whether [declaratory relief] would finally settle the controversy between the parties; whether other remedies are available or other proceedings pending; the convenience of the parties; the equity of the conduct of the declaratory judgment plaintiff; prevention of ‘procedural fencing‘; the state of the record; the degree of adverseness between the parties; and the public importance of the question to be decided.
The balance of the relevant factors counsels against exercising jurisdiction over this action. Generally, in the interest of judicial efficiency, courts decline to hear declaratory judgment actions that would not fully resolve the parties’ claims. See Roth v. D.C. Courts, 160 F.Supp.2d 104, 110 (D.D.C.2001). Here, if the court resolved the issues POM raised in its declaratory judgment action, the parties would still have to litigate whether POM‘s health claims about its products were false, misleading, and unsubstantiated in violation of the FTC Act.
In addition, other overlapping proceedings are pending. The FTC filed an administrative complaint against POM two weeks after POM filed its complaint for declaratory relief. While the administrative proceeding is not identical to POM‘s current action, that forum is “perfectly capable” of determining whether the proposed order exceeds the bounds of the FTC Act, violates the First and Fifth Amendments, and seeks to abrogate the FDA‘s power. See Patton Boggs, LLP v. Chevron Corp., 791 F.Supp.2d 13, 25 (D.D.C.2011). POM can raise and has raised in the FTC‘s parallel enforcement action several of the same arguments that it is pursuing in this action. The enforcement action may not fully resolve POM‘s claims that the FTC has violated the APA and its own rulemaking procedures in adopting a new standard in the Nestlé and Iovate consent orders and that its “new rule” is arbitrary and capricious, but POM will have a full opportunity to challenge any FTC final action against it upon the conclusion of the administrative action with a fully developed administrative record available.
Another factor that weighs against exercising jurisdiction is when “granting declaratory relief would require the resolu-
In POM‘s answer to the FTC‘s administrative complaint, it raised several affirmative defenses including that the FTC does not have authority under the FTC Act, the APA, and the First and the Fifth Amendments of the U.S. Constitution to seek the proposed order and that the FTC is attempting to enforce a new standard on POM “without adequate notice to the public.” (Answer at 7, In the Matter of POM Wonderful, et al., No. 9344 (F.T.C. Oct. 18, 2010).) In the instant action, POM is seeking a declaratory judgment on both affirmative defenses. At least two of the four causes of action asserted in POM‘s declaratory judgment action are properly considered anticipatory defenses.
These and other Hanes factors militate against this court exercising its jurisdiction over POM‘s complaint for declaratory relief. Courts should not allow parties to use the Declaratory Judgment Act to engage in forum shopping. “Thus, in examining whether to resolve a declaratory judgment action, ‘[c]ourts take a dim view of declaratory plaintiffs who file their suits mere days or weeks before the coercive suits filed by a ‘natural plaintiff’ and who seem to have done so for the purpose of acquiring a favorable forum.‘” Swish Mktg., 669 F.Supp.2d at 78 (quoting AmSouth Bank v. Dale, 386 F.3d 763, 788 (6th Cir.2004)). Here, the FTC asserts that when POM filed its declaratory judgment action, it was aware that the FTC would soon file an administrative complaint against it. (Def.‘s Mem. at 5.) As POM does not dispute this allegation, POM‘s conduct leaves the disfavored appearance that POM hastily filed the instant case, in part, to secure tactical leverage from proceedings in this forum. Moreover, the administrative enforcement action has proceeded through discovery and oral arguments were scheduled. (See Order Scheduling Oral Argument at 1, In re POM Wonderful LLC, et al., No. 9344 (F.T.C. June 21, 2012).) Continuing this parallel matter would not aid in the orderly progress of resolving the parties’ disputes. Yielding here while the administrative action proceeds will not significantly prejudice POM.
CONCLUSION
The relevant Hanes factors counsel against exercising jurisdiction over POM‘s declaratory action. Therefore, the defendant‘s motion to dismiss will be granted.
A separate Order accompanies this Memorandum Opinion.
